Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.52 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.52 |
| ▸ | ITGAL | P20701 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | EIF4E | P06730 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198442 | 0.89 | KDM4E (0.56) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL1198946 | 0.87 | KDM4E (0.47) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL12875697 | 0.87 | SIRT5 (0.44) | KDM4EALDH1A1MEN1KMT2AITGB3 | |
| SCHEMBL1198469 | 0.86 | KDM4E (0.44) | KDM4EALDH1A1MEN1KMT2AEIF4E | |
| SCHEMBL1198344 | 0.85 | KDM4E (0.47) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL1199217 | 0.83 | KDM4E (0.61) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL1198797 | 0.82 | KDM4E (0.53) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL1199380 | 0.82 | PTGER1 (0.52) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL1198552 | 0.82 | ALDH1A1 (0.51) | ITGB2ICAM1ITGALKDM4EALDH1A1 | |
| SCHEMBL1198783 | 0.81 | ITGB2 (0.71) | ITGB2ICAM1ITGALKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | ITGB2 2981/4885ICAM1 1399/4885ITGAL 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.